Rising had hiked the price of the tablets by 98 percent between December 2019 and January, from $3.87 per tablet to $7.66 per tablet. But in response to growing demand for the drug amid the coronavirus pandemic, Rising said it would cut the price in half. It later decided to lower it an additional 20 percent.
The initial price hike came before the new coronavirus outbreak turned into a pandemic and before public health officials believed chloroquine could effectively treat COVID-19, Rising told STAT.
Chloroquine has been made as an antimalarial treatment since the late 1940s and is often used to treat lupus and rheumatoid arthritis. Ira Baerigner, Rising’s COO, emphasized to STAT that the drugmaker isn’t marketing its chloroquine pills as a COVID-19 treatment, since the FDA hasn’t approved it for that use.
Read the full article here.
More articles on pharmacy:
CVS Health recruiting 50,000 workers amid COVID-19 pandemic
69 experimental COVID-19 drugs, treatments identified
Physicians found hoarding experimental COVID-19 treatments for relatives, report says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
